$343 Million is the total value of Knoll Capital Management, LLC's 17 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 107.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVN | Sell | Medivation, Inc. | $283,814,000 | +28.1% | 2,198,919 | -2.0% | 82.63% | -5.2% |
| AMPE | Ampio Pharmaceuticals Inc. | $25,514,000 | +119.5% | 3,388,322 | 0.0% | 7.43% | +62.5% | |
| SYN | Synthetic Biologics Inc. | $7,448,000 | +50.0% | 3,400,816 | 0.0% | 2.17% | +11.0% | |
| ADHD | Buy | Alcobra Ltd | $6,279,000 | +94.5% | 1,115,315 | +28.9% | 1.83% | +43.9% |
| NLNK | Buy | Newlink Genetics Corp | $5,604,000 | +82.1% | 102,437 | +32.3% | 1.63% | +34.8% |
| ADXS | New | Advaxis Inc. | $3,971,000 | – | 275,000 | +100.0% | 1.16% | – |
| KERX | Keryx Biopharmaceuticals Inc. | $2,546,000 | -10.0% | 200,000 | 0.0% | 0.74% | -33.5% | |
| ORPN | Bio Blast Pharma Ltd | $2,029,000 | -6.1% | 338,110 | 0.0% | 0.59% | -30.5% | |
| ALDX | New | Aldeyra Therapeutics Inc | $1,382,000 | – | 135,800 | +100.0% | 0.40% | – |
| LBIO | New | Lion Biotechnologies Inc | $1,211,000 | – | 100,000 | +100.0% | 0.35% | – |
| ADXSW | New | Advaxis Inc.w exp 07/15/201 | $1,170,000 | – | 112,500 | +100.0% | 0.34% | – |
| PTBI | New | PlasmaTech Biopharmaceutical | $669,000 | – | 213,100 | +100.0% | 0.20% | – |
| GLMD | Galmed Pharmaceuticals Ltd | $612,000 | +62.3% | 65,000 | 0.0% | 0.18% | +20.3% | |
| OHRP | New | OHR Pharmaceutical Inc | $521,000 | – | 205,000 | +100.0% | 0.15% | – |
| EVOK | New | Evoke Pharma Inc | $380,000 | – | 53,839 | +100.0% | 0.11% | – |
| ZSAN | New | Zosano Pharma Corp | $202,000 | – | 20,000 | +100.0% | 0.06% | – |
| New | Aptose Biosciences Inc | $108,000 | – | 20,000 | +100.0% | 0.03% | – | |
| NRXGQ | Exit | Nephrogenex Inc | $0 | – | -3,072 | -100.0% | -0.02% | – |
| PVCT | Exit | Provectus Biopharmaceuticals | $0 | – | -200,000 | -100.0% | -0.06% | – |
| Exit | Advaxis Inc.w exp 07/15/201 | $0 | – | -112,500 | -100.0% | -0.18% | – | |
| INO | Exit | Inovio Pharmaceuticals Inc. | $0 | – | -82,088 | -100.0% | -0.30% | – |
| ASPX | Exit | Auspex Pharmaceuticals Inc. | $0 | – | -20,000 | -100.0% | -0.41% | – |
| Exit | Advaxis Inc. | $0 | – | -225,000 | -100.0% | -0.71% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.